Fda trelegy ellipta?

Trelegy Ellipta is an FDA-approved inhaled medicine for COPD, not asthma. It is a triple therapy that combines three drugs in one inhaler: fluticasone furoate (steroid), umeclidinium (LAMA), and vilanterol (LABA).

Key points:
- Indication (FDA): maintenance treatment to reduce COPD exacerbations in adults. Not for relief of sudden symptoms or acute bronchospasm.
- Dose: one inhalation once daily. Each inhalation contains fluticasone furoate 100 mcg / umeclidinium 55 mcg / vilanterol 25 mcg.
- Not for: asthma (not approved for asthma), not a rescue inhaler.
- Common precautions: risk of pneumonia in COPD, oral thrush and hoarseness from the inhaled steroid, check for infections, monitor for cardiovascular effects, and use only as prescribed.

If you’d like, I can pull up the exact FDA labeling or provide more details on who should or shouldn’t use it.